...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Parasites Vectors >An alternative mebendazole formulation for cystic echinococcosis: the treatment efficacy, pharmacokinetics and safety in mice
【24h】

An alternative mebendazole formulation for cystic echinococcosis: the treatment efficacy, pharmacokinetics and safety in mice

机译：囊性超声波病变的替代兆唑配方：小鼠治疗疗效，药代动力学和安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Cystic echinococcosis is a serious zoonotic infection worldwide caused by metacestodes of Echinococcus gruanulosus. Mebendazole and albendazole are the only two drugs used in the treatment of this disease with cure rates only about 30% due to the poor oral absorption. Thus an alternative treatment for this disease is needed. Methods A mebendazole oily suspension (MBZ-OS) was prepared and orally administrated to mice infected with echinococcus cysts for 8 months at 12.5 mg/kg and 25 mg/kg for 14 consecutive days. Mebendazole suspended in 1% tragacanth (MBZ-1% tragacanth) served as treated control. In addition, liver and serum samples were collected from these treated mice (25 mg/kg) for histopathology examination and liver function test. For pharmacokinetic analysis, plasma, parasite (cyst wall and cyst fluid) and tissue samples were collected at 0.25, 0.5, 1, 2, 4, 8, 16 and 24 h after orally administrating MBZ-OS and MBZ-1% tragacanth to E. granulosus-infected mice at 25 mg/kg. These samples were then processed and quantitatively analyzed by HPLC. Results The administration of MBZ-OS resulted in a treatment efficacy with the cyst weight reductions higher than 80%, significantly better than the corresponding MBZ-1% tragacanth groups. The better treatment efficacy of MBZ-OS was related to the higher drug concentration in plasma, parasites and tissues. It was also shown that the injury of the liver was not significantly altered by taking MBZ-OS compared to the untreated control. Conclusion These findings demonstrate that MBZ-OS is a promising new formulation of MBZ for treatment of hydatid diseases without showing significantly liver toxicity.
机译：背景技术囊性超声波功能率为全世界是由Echinococcus Gruanulosus的Metacestodes引起的全世界严重的动物感染。 Mebendazole和Albendazole是唯一用于治疗这种疾病的唯一药物，其治疗率仅约为30％，由于口服不良。因此需要对这种疾病进行替代治疗方法。方法制备兆唑油含量悬浮液（MBZ-OS），并口服给予用Echinococcus囊肿感染8个月的小鼠，连续14天在12.5mg / kg和25mg / kg。 Meandazole悬浮在1％Tragacanth（MBZ-1％Tragacancth）中作为处理的对照。此外，从这些处理的小鼠（25mg / kg）收集肝脏和血清样品，用于组织病理学检查和肝功能试验。对于药代动力学分析，在口服MBZ-OS和MBZ-1％Tragacanth至E之后在0.25,0.5,1,2,4,8,16和24小时收集血浆，寄生虫（囊岩和囊囊液）和组织样品。颗粒感染小鼠，25毫克/千克。然后通过HPLC处理和定量分析这些样品。结果施用MBZ-OS导致治疗效果，囊肿重量高于80％，明显优于相应的MBZ-1％曲折基团。 MBZ-OS的更好的治疗效果与血浆，寄生虫和组织中的较高药物浓度有关。还表明，与未处理的对照相比，通过将MBZ-OS进行肝脏的损伤不会显着改变。结论这些研究结果表明，MBZ-OS是MBZ的有希望的新配方，用于治疗纳米湿疾病而不显示出显着肝脏毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号